News Sentiment

ACAD sentiment intelligence

ACADIA Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 26.22 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+1.0% over one week, +24.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Acadia Pharmaceuticals to announce Q2 2026 results on August 4

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 1.0% Price digesting
Trend fit Trend inactive 24.3% over four weeks
Fair value 23.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 31
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 6
TradingView 5
simplywall.st 5
Sahm 3
Simply Wall Street 3
Moomoo 3
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 17
Analyst action 4
Regulatory and legal 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
scanx.trade Direct company coverage

Acadia Pharmaceuticals to announce Q2 2026 results on August 4

Acadia Pharmaceuticals Inc. is set to release its Q2 2026 financial results on August 4, 2026, after the U.S. financial markets close. Following the release, the company will host a conference call and webcast at 4:30 p.m. ET to discuss its performance. This event will be accessi

Tone
Positive 64/100
Event
Earnings
Published
15 Jul 2026 22:14
Source
scanx.trade
The Globe and Mail Direct company coverage

H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

H.C. Wainwright analyst Ananda Ghosh reiterated a Buy rating for ACADIA Pharmaceuticals (ACAD) on July 7, setting a price target of $27.00. This follows other analyst actions, with RBC Capital also giving a Buy rating, while Morgan Stanley maintained a Hold rating. The company re

Tone
Positive 72/100
Event
Analyst action
Published
11 Jul 2026 00:41
Source
The Globe and Mail
Sahm Direct company coverage

ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% Run

ACADIA Pharmaceuticals (ACAD) stock has seen a 20.5% return over the past year but is still considered undervalued based on current checks. Despite positive news from the European Medicines Agency regarding Daybu, the stock's P/E ratio of 11.9x is significantly below the biotech

Tone
Positive 69/100
Event
Market update
Published
10 Jul 2026 15:39
Source
Sahm
Market source Direct company coverage

How CHMP’s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors

ACADIA Pharmaceuticals received a positive opinion from the EMA's CHMP for DAYBU to treat Rett syndrome in Europe, potentially making it the first approved therapy for the condition in the EU. This development could expand treatment options for patients and reinforce Acadia's rev

Tone
Positive 74/100
Event
Market update
Published
10 Jul 2026 13:39
Source
Market source
Simply Wall Street Direct company coverage

Is ACADIA Pharmaceuticals (ACAD) Undervalued On Rett Progress And Its Leadership Change?

ACADIA Pharmaceuticals is gaining attention due to a recent leadership appointment and a positive European regulatory opinion for its Rett syndrome therapy, DAYBU. The company's stock has seen strong performance with a 20.9% return over 30 days and a 19.7% one-year return. Despit

Tone
Positive 70/100
Event
Regulatory and legal
Published
10 Jul 2026 13:39
Source
Simply Wall Street
Sahm Direct company coverage

Should EMA’s Positive Rett Syndrome Opinion for DAYBU Reshape ACADIA Pharmaceuticals’ (ACAD) Investment Narrative?

ACADIA Pharmaceuticals recently received positive news from the European Medicines Agency (EMA) regarding DAYBU (trofinetide) for Rett syndrome, potentially expanding its market in Europe. While this development could strengthen DAYBU's position as a second revenue pillar next to

Tone
Positive 66/100
Event
Earnings
Published
08 Jul 2026 23:39
Source
Sahm
TradingView Direct company coverage

Enterprise value to EBITDA forward of ACADIA Pharmaceuticals Inc. – NASDAQ:ACAD

This page displays the enterprise value to EBITDA forward for ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). The data is provided by ICE Data Services and FactSet, focusing on the financial metrics for the company within the pharmaceuticals sector.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 01:11
Source
TradingView
BioSpace Direct company coverage

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

Acadia Pharmaceuticals Inc. has announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6, 2026. Segerstrom will oversee the company's global people and culture strategy, supporting its expansion as a leading neurological and rare disease company. He

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 11:40
Source
BioSpace
Stock Titan Direct company coverage

Acadia taps 25-year HR veteran for chief people officer role

Acadia Pharmaceuticals Inc. has appointed Carl Segerstrom as its new Chief People Officer, effective July 6. Segerstrom, who brings over 25 years of global human resources experience from the biopharmaceutical industry, will lead the company's people and culture strategy to suppo

Tone
Positive 71/100
Event
Market update
Published
06 Jul 2026 12:40
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of ACADIA Pharmaceuticals Inc. – LSX:603035

The article discusses the "Price to book forward" metric for ACADIA Pharmaceuticals Inc. (LSX:603035). It appears to be a financial data snippet from TradingView, indicating that the market for this stock was closed with no trades recorded. The content does not provide specific f

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 22:40
Source
TradingView
Finviz Direct company coverage

ACAD - Acadia Pharmaceuticals Inc Forecast, Target Price

This article provides comprehensive financial data for Acadia Pharmaceuticals Inc. (ACAD), including key metrics like market capitalization, P/E ratio, EPS forecasts, and sales performance. It also details insider and institutional ownership, profitability ratios, and various sto

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 22:40
Source
Finviz
TradingView Direct company coverage

Price to sales forward of ACADIA Pharmaceuticals Inc. – NASDAQ:ACAD

This article provides access to the "Price to sales forward" financial metric for ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on TradingView. It indicates that the market was closed at the time of publication and offers no trades. The content primarily focuses on navigation to fin

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 13:11
Source
TradingView
TMX Newsfile Direct company coverage

ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now

Hagens Berman, a national trial law firm, is alerting investors of Acadia Pharmaceuticals (NASDAQ: ACAD) to a securities class action lawsuit. The lawsuit alleges that Acadia misrepresented facts concerning its supplemental new drug application ("sNDA") for NUPLAZID® (pimavanseri

Tone
Negative 18/100
Event
Regulatory and legal
Published
01 Jul 2026 21:09
Source
TMX Newsfile
Simply Wall Street Direct company coverage

ACADIA Pharmaceuticals (ACAD) In Focus As Europe Backs Daybue And Undervalued View Holds

ACADIA Pharmaceuticals (ACAD) shares are in focus after European regulators issued a positive opinion on Daybue for Rett syndrome, causing a recent rally. Despite a 16.34% one-month return, the stock is still down 4.15% year-to-date and is considered 12.3% undervalued with a fair

Tone
Positive 71/100
Event
Market update
Published
30 Jun 2026 20:10
Source
Simply Wall Street
Investing.com Direct company coverage

H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating on EU progress

H.C. Wainwright reaffirmed its Buy rating and $37 price target for Acadia Pharmaceuticals (NASDAQ:ACAD) after the CHMP issued a positive opinion for DAYBU (trofinetide) in Europe. This decision reverses a previous refusal and recommends marketing authorization for neurobehavioral

Tone
Positive 70/100
Event
Analyst action
Published
30 Jun 2026 12:09
Source
Investing.com
Investing.com Canada Direct company coverage

Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com

This article announces the filing of Form 4 for ACADIA Pharmaceuticals Inc. on June 29. It includes basic information about the company and its stock performance, along with a statement from Reuters. The primary content is a headline and brief stock data.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 22:09
Source
Investing.com Canada
Stock Titan Direct company coverage

ACADIA PHARMACEUTICALS (ACAD) officer sells 11,421 shares under 10b5-1 plan

ACADIA PHARMACEUTICALS' Principal Accounting Officer, James Kihara, sold 11,421 shares of common stock at a weighted average price of $26.0846 per share. This open-market transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. Follow

Tone
Negative 37/100
Event
Market update
Published
29 Jun 2026 21:41
Source
Stock Titan
Sahm Direct company coverage

Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher after the European Medicines Agency (CHMP) recommended granting marketing authorization for its drug DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in the EU. This follows an earlier nega

Tone
Positive 72/100
Event
Market update
Published
28 Jun 2026 20:39
Source
Sahm
Simply Wall Street Direct company coverage

Why ACADIA Pharmaceuticals (ACAD) Is Up 17.1% After EMA Backs DAYBU For Rett Syndrome

ACADIA Pharmaceuticals saw its stock rise by 17.1% after the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for DAYBUE (trofinetide) to treat Rett syndrome in the EU. This potential approval would make DAYBUE the first approved therapy for

Tone
Positive 82/100
Event
Regulatory and legal
Published
28 Jun 2026 07:39
Source
Simply Wall Street